Maxim, And Samyang now owns almost 20% of Cortex, 25% if they exercise the warrants. They're getting well down the road toward ownership/control of the company. But they're getting it very cheap, so far a mere $2 mil has bought them 20% ownership.
I wonder if this proposed licensing deal will allow Samyang to run their own clinical trials with Cortex's compounds? That's a big negative from another pharma's perspective, since Samyang could bungle the trial and thus poison the well for CX-1739 and CX-1846. Varney still needs to partner these key compounds to a Pharma for the US and European territories, and for other indications.
Market Data 
Markets 
AI
